Senores Pharmaceuticals Limited has issued a postal ballot notice seeking shareholder approval for the re-appointment of its top leadership. The resolutions concern the continuation of Swapnil Jatinbhai Shah as Managing Director and Chetan Bipinchandra Shah as Whole Time Director for a fresh three-year term. Remote e-voting commenced on October 19, 2026, and will conclude on November 17, 2026.

The Board of Directors approved these proposals in a meeting held on October 13, 2026, following recommendations from the Nomination and Remuneration Committee and the Audit Committee. The notice was sent electronically to members whose names appeared in the Register of Members as of the cut-off date, October 9, 2026. Results will be declared on or before November 19, 2026.

Leadership Continuity and Terms

Swapnil Jatinbhai Shah, the Promoter and Managing Director, is proposed for re-appointment for a term of three years commencing October 15, 2026, to October 14, 2029. His current tenure was due to expire on October 14, 2026. The resolution seeks to continue his remuneration at ₹7.50 crore per annum, which remains unchanged from his previous package. Shah has over 18 years of experience in the pharmaceutical sector and previously served as a strategist at Planet Payment Inc.

Chetan Bipinchandra Shah, Whole Time Director and Chief Operating Officer, is proposed for re-appointment for a term of three years commencing November 10, 2026, to November 9, 2029. His current tenure expires on November 9, 2026. The proposal includes a revision in his remuneration to ₹1.90 crore per annum with effect from October 1, 2026. This represents an increase of approximately 11.76% from his FY26 drawn remuneration of ₹1.70 crore. Shah brings over 30 years of experience, including 25 years in the pharmaceutical industry with prior stints at Torrent Pharmaceuticals and Cadila Pharmaceuticals.

Financial Performance Context

The re-appointments come against a backdrop of significant consolidated growth for the company. The explanatory statement highlights the financial performance for the last three fiscal years, demonstrating a sharp upward trajectory in revenue and profitability.

The data indicates that Total Revenue grew from ₹40.85 crore in FY24 to ₹172.44 crore in FY26. Concurrently, Net Profit after Tax expanded from ₹0.81 crore in FY24 to ₹20.25 crore in FY26. Reserves and Surplus also saw substantial accumulation, rising from ₹137.61 crore in FY24 to ₹703.85 crore in FY26.

What the Numbers Show

A comparative analysis of director remuneration against company profitability reveals a divergence in growth rates. While the company's Net Profit after Tax grew significantly from ₹3.69 crore in FY25 to ₹20.25 crore in FY26, the Managing Director's remuneration remained flat at ₹7.50 crore across both years. In contrast, the Whole Time Director's remuneration increased from ₹1.20 crore in FY25 to ₹1.70 crore in FY26, with a further proposed hike to ₹1.90 crore for the upcoming term. This suggests that while the MD's compensation has been held constant despite exponential profit growth, the COO's compensation is being adjusted upwards, potentially reflecting specific operational responsibilities or market benchmarking adjustments for that role.

Voting Procedure

Shareholders can cast their votes through remote e-voting facilitated by MUFG Intime India Private Limited. Voting rights are proportionate to the share of paid-up equity capital held as of the cut-off date. Members holding shares in demat mode can vote via NSDL or CDSL portals or directly through the InstaVote platform. Institutional shareholders must follow specific registration and mapping procedures to exercise their votes. The scrutinizer appointed for this process is Mukesh H. Shah & Co., Company Secretaries in Practice.

Senores Pharmaceuticals Limited held its ninth Annual General Meeting (AGM) on September 25, 2026. The meeting was conducted through video conferencing and other audio-visual means, complying with regulatory guidelines for virtual gatherings.

Shareholders approved several key resolutions during the session. The most significant corporate action was the approval of the Senores Pharmaceuticals Employee Stock Option Scheme 2026. This special resolution allows the company to grant stock options to employees, including those working in subsidiary companies, aiming to align employee interests with long-term shareholder value.

Voting results and shareholder sentiment

The scrutinizer’s report, filed on September 28, 2026, detailed the voting outcomes for each resolution. While promoters voted unanimously in favour of all agenda items, public shareholders displayed mixed reactions, particularly regarding director appointments and the new ESOP scheme.

For the adoption of financial statements and the appointment of the new independent director, Mr. Viranchi Arvindbhai Shah, support was near-universal across all categories. However, dissent was notable in two specific resolutions:

1. Re-appointment of Mr. Arpit Deepakkumar Shah: Public institutions cast 46.71% of their votes against this ordinary resolution. Despite this, the resolution passed with 93.78% total votes in favour due to overwhelming promoter support.
2. ESOP Scheme Approval: Public institutions voted 46.45% against the Employee Stock Option Scheme 2026. Similarly, the grant of options to subsidiary employees faced 46.45% opposition from institutions. Both special resolutions passed with 93.81% overall support.

Director appointments and re-elections

The board composition saw minor changes with the re-appointment of existing directors and the induction of a new independent director. Mr. Sanjay Shaileshbhai Majmudar and Mr. Arpit Deepakkumar Shah were re-appointed as directors following their retirement by rotation. Additionally, Mr. Viranchi Arvindbhai Shah was appointed as a Non-Executive Independent Director for a term of five consecutive years.

Meeting proceedings and attendance

The AGM commenced at 11:31 am and concluded at 12:02 pm IST. A total of 49 members attended the meeting virtually, including representatives from corporate bodies. The meeting was chaired by Mr. Sanjay Shaileshbhai Majmudar, Chairman and Non-Executive, Non-Independent Director.

Key managerial personnel and auditors were present to address shareholder queries. M/s Pankaj R. Shah & Associates served as statutory auditors, while M/s Sharp and Tannan Associates acted as internal auditors. Mr. Mukesh H. Shah from M/s Mukesh H. Shah & Co. served as the secretarial auditor and scrutinizer for the voting process.

Resolutions passed

The following resolutions were transacted at the meeting:

Voting results required under Regulation 44(3) of the SEBI LODR Regulations have been submitted to BSE and NSE. The full proceedings are available on the company’s official website.